secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-116023
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q1 net loss $62.3M; cash $565M; iMMagine-3 adds MRD endpoint
--------------------------------------------------------------------

- Net loss of $62.3M vs $7.2M in Q1 2024; collaboration revenue down to $8.1M from $39.3M.
- Cash and equivalents $565.2M; funding expected into 2028.
- iMMagine-1 data (117 patients) accepted for oral presentation at EHA June 14, 2025.
- iMMagine-3 study updated to include MRD negativity as dual primary endpoint alongside PFS.
- Appointed Andrew Galligan and Kristin Myers to Board; anito-cel launch planned for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/0001193125-25-116023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312525116023/d916048d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-116023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer